A
Ann Namkung
Researcher at AIDS Clinical Trials Group
Publications - 4
Citations - 295
Ann Namkung is an academic researcher from AIDS Clinical Trials Group. The author has contributed to research in topics: Immunopathology & Immunization. The author has an hindex of 4, co-authored 4 publications receiving 290 citations. Previous affiliations of Ann Namkung include Rush University Medical Center.
Papers
More filters
Journal ArticleDOI
Age-Related Immune Dysfunction in Health and in Human Immunodeficiency Virus (HIV) Disease: Association of Age and HIV Infection with Naive CD8+ Cell Depletion, Reduced Expression of CD28 on CD8+ Cells, and Reduced Thymic Volumes
Robert C. Kalayjian,Robert C. Kalayjian,Alan L. Landay,Richard B. Pollard,Dennis D. Taub,Barry H. Gross,Isaac R. Francis,Anne Sevin,Minya Pu,John Spritzler,Miriam Chernoff,Ann Namkung,Lawrence Fox,Ana Martinez,Karen Waterman,Susan A. Fiscus,Beverly E. Sha,Debra Johnson,Stanley Slater,Frank Rousseau,Michael M. Lederman +20 more
TL;DR: Because of their common association with age and HIV disease, naive CD8(+) cell depletion, diminished CD28 expression on CD8 (+) cells, and reduced thymic volumes are possible correlates of the interaction of age with HIV disease.
Journal ArticleDOI
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s.
Hernan Valdez,Ronald T. Mitsuyasu,Alan L. Landay,Anne Sevin,Ellen S. Chan,John Spritzler,Spyros A. Kalams,Richard B. Pollard,John L. Fahey,Lawrence Fox,Ann Namkung,Scharla Estep,Ronald B. Moss,David Sahner,Michael M. Lederman +14 more
TL;DR: In this paper, a human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy (HAART) or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines.
Lymphocyte Numbers but Does Not Enhance Responses to Immunization: Results of A5046s
Hernan Valdez,Ronald T. Mitsuyasu,Alan L. Landay,Anne Sevin,Ellen S. Chan,John Spritzler,Spyros A. Kalams,Richard B. Pollard,John L. Fahey,Lawrence Fox,Ann Namkung,Scharla Estep,Ronald B. Moss,David Sahner,Michael M. Lederman +14 more
TL;DR: To ascertain whether CD4(+) lymphocyte increases induced by interleukin (IL)-2 enhanced in vivo immune responses, 38 human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines.
Journal ArticleDOI
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
Beverly E. Sha,Hernan Valdez,Rebecca Gelman,Alan L. Landay,Jan Agosti,Ronald T. Mitsuyasu,Richard B. Pollard,Donna Mildvan,Ann Namkung,Debra Ogata-Arakaki,Lawrence Fox,Scharla Estep,Alejo Erice,Patrick Kilgo,Robert E. Walker,Lynne Bancroft,Michael M. Lederman +16 more
TL;DR: The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel) on plasma cytokines was evaluated in HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2).